Literature DB >> 28098572

Metastatic Organotropism: An Intrinsic Property of Breast Cancer Molecular Subtypes.

Shi Wei1, Gene P Siegal.   

Abstract

It has long been known that some cancers have the propensity to metastasize to certain organs thus creating a nonrandom distribution of sites for distant relapse, a phenomenon known as "metastatic organotropism." Some of these examples include ovary primary to abdominal cavity, prostate primary to bone, and pancreas primary to liver. In contrast, other tumor types, such as mammary and renal cell carcinoma, can relapse in multiple organs although approximately half of advanced breast cancers metastasize to bone. On the other hand gene expression profiling studies have identified various breast cancer classes with prognostic significance. Recent studies have revealed that breast cancer subtypes differ not only in primary tumor characteristics but also in their metastatic behavior. In particular, the luminal tumors are remarkable for their significant bone-seeking phenotype; the HER2 subtype demonstrates a significant liver-homing characteristic; whereas so-called triple-negative breast cancers predispose to lung metastases. These findings suggest that this knowledge could potentially be utilized in the development of effective disease surveillance strategies in the pursuit of precision medicine, thus necessitating further investigation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28098572     DOI: 10.1097/PAP.0000000000000140

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  7 in total

1.  A pathways-based prediction model for classifying breast cancer subtypes.

Authors:  Tong Wu; Yunfeng Wang; Ronghui Jiang; Xinliang Lu; Jiawei Tian
Journal:  Oncotarget       Date:  2017-06-17

2.  A retrospective prognostic evaluation analysis using the 8th edition of American Joint Committee on Cancer (AJCC) cancer staging system for luminal A breast cancer.

Authors:  Jingming Ye; Wenjun Wang; Ling Xu; Xuening Duan; Yuanjia Cheng; Ling Xin; Hong Zhang; Shuang Zhang; Ting Li; Yinhua Liu
Journal:  Chin J Cancer Res       Date:  2017-08       Impact factor: 5.087

3.  DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy.

Authors:  Cynthia Bernier; Ahmed Soliman; Michel Gravel; Matthew Dankner; Paul Savage; Kevin Petrecca; Morag Park; Peter M Siegel; Gordon C Shore; Anne Roulston
Journal:  Anticancer Drugs       Date:  2018-09       Impact factor: 2.248

4.  Epidural adipose tissue-derived mesenchymal stem cell activation induced by lung cancer cells promotes malignancy and EMT of lung cancer.

Authors:  Yan Wang; Yijing Chu; Xianfeng Ren; Hongfei Xiang; Yongming Xi; Xuexiao Ma; Kai Zhu; Zhu Guo; Chuanli Zhou; Guoqing Zhang; Bohua Chen
Journal:  Stem Cell Res Ther       Date:  2019-06-13       Impact factor: 6.832

5.  Notch2 pathway mediates breast cancer cellular dormancy and mobilisation in bone and contributes to haematopoietic stem cell mimicry.

Authors:  Mattia Capulli; Dayana Hristova; Zoé Valbret; Kashmala Carys; Ronak Arjan; Antonio Maurizi; Francesco Masedu; Alfredo Cappariello; Nadia Rucci; Anna Teti
Journal:  Br J Cancer       Date:  2019-06-26       Impact factor: 7.640

Review 6.  From women to women-hematuria during therapy for metastatic breast cancer, what to suspect and when to be alarmed; Bladder metastasis from breast cancer-our experience and a systematic literature review.

Authors:  Rafaela Malinaric; Federica Balzarini; Giorgia Granelli; Arianna Ferrari; Giorgia Trani; Francesca Ambrosini; Guglielmo Mantica; Daniele Panarello; Aldo Franco De Rose; Carlo Terrone
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

7.  Cell Cytoskeleton and Stiffness Are Mechanical Indicators of Organotropism in Breast Cancer.

Authors:  Kai Tang; Ying Xin; Keming Li; Xi Chen; Youhua Tan
Journal:  Biology (Basel)       Date:  2021-03-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.